Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering parental vaccine hesitancy, changes to a key federal vaccine committee, and growing workforce pressures in healthcare. A…

In a video interview with Pharma Commerce, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at calls for rural hospital funding, vaccination gaps among adults with celiac disease, and a multi-billion-dollar pharma…

In a video interview with Pharma Commerce, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new FDA guidance on pain management, an FTC warning on healthcare employment practices, and a major acquisition…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering the latest measles outbreak in Florida, new scrutiny of pharma advertising, and a cost-effectiveness review of obesity…

Ned Milenkovich, PharmD, JD The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients Register for the full webinar here! President Trump’s executive order pushing for most-favored-nation (MFN) pricing for pharmaceuticals sent shockwaves through the industry. While most people agree that healthcare and…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at potential new trade restrictions on China-discovered treatments, fresh clinical data on Pfizer and BioNTech’s COVID-19 vaccine,…

Mark Kunar of DHL Supply Chain North America (left) and Drew Kronick of SDS Rx (right). Image Credit: DHL Supply Chain DHL Supply Chain has officially agreed to purchase SDS Rx, a provider of final-mile delivery and specialized healthcare transportation services for long-term care and specialty pharmacies, radiopharmacies, and health…

In a video interview with Pharma Commerce, Derrick Gastineau, Head of Marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the…

Image Credit: Adobe Stock Images/Wichayada.com According to FirstWord Pharma, Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, has inked a $1.3 billion production contract with a mega pharma partner in a deal that is expected to run until the end of 2029.1 A corporate filing…

Drug shortages continue to create significant financial and operational strain on hospitals, impacting both patient care and workforce efficiency. In a video interview with Pharma Commerce, Boyede Sobitan, global healthcare strategy lead, and Annika Matas,senior director of product management and business operations, supplies and sensors—both with Zebra Technologies—they describe how hospitals…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a major cardiovascular acquisition by Novartis, new research into flu severity in older adults, and practical solutions…

Image Credit: Adobe Stock Images/Enigma Topline Findings Significant Weight Loss Achieved: Zepbound delivers 17.8%–20.8% average weight loss, while injectable Wegovy achieves 14%–17%, and oral Wegovy 11.4%, highlighting effective obesity management options. Cost-Effectiveness Highlighted: All therapies are highly cost-effective at conventional thresholds, with QALY estimates of $53,400 for tirzepatide, $61,400 for…

Image Credit: Adobe Stock Images/Jordi.com Ascensia Diabetes Care—a part of PHC Group—has signed a memorandum of understanding (MOU) to transfer the commercial operations for its branded Eversense Continuous Glucose Monitoring (CGM) systems to Eversense designer Senseonics Holdings, Inc.1 Pending an official agreement, the parties are aiming to merge Eversense R&D,…

Drug shortages continue to create significant financial and operational strain on hospitals, impacting both patient care and workforce efficiency. In a video interview with Pharma Commerce, Boyede Sobitan, global healthcare strategy lead, and Annika Matas, senior director of product management and business operations, supplies and sensors—both with Zebra Technologies—they describe how…

Sharmeen Roy, PharmD, BCPS The pharmaceutical industry’s digital shift now influences not just R&D, but delivery, pricing, and utilization. Precision dosing, powered by model-informed tools such as Bayesian analytics and real-time pharmacokinetic modeling, is no longer a clinical “nice-to-have.” It’s a boardroom lever. While the clinical benefits of model-informed precision…

Drug shortages continue to create significant financial and operational strain on hospitals, impacting both patient care and workforce efficiency. In a video interview with Pharma Commerce, Boyede Sobitan, global healthcare strategy lead, and Annika Matas, senior director of product management and business operations, supplies and sensors—both with Zebra Technologies—they describe how…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at a new FDA approval in rare disease, fresh evidence on the impact of Rx-to-OTC drug switches,…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a major R&D investment from Amgen, a multi-billion-dollar acquisition by Novartis, and new head-to-head data on GLP-1…

Avinob Roy, Vice President & General Manager of Global Commercial Product Offerings at IQVIA, spoke with Pharmaceutical Commerce about how advancements in AI, particularly agentic AI, are reshaping the future of commercial operations in life sciences. From understanding disease landscapes and identifying patient populations to optimizing brand strategy and field…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering the latest legal battle over pharmaceutical tariffs, Sanofi’s market setback following Phase III results, and new research…

Image Credit: Adobe Stock Images/SundryPhotography.com Gilead Sciences has unveiled its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC), nestled in the company’s Foster City, CA headquarters.1 The new 180,000 square-foot plant spans five stories, and represents another accomplished goal in Gilead’s multi-year plan to generate growth and scientific leadership…

Drug shortages continue to create significant financial and operational strain on hospitals, impacting both patient care and workforce efficiency. In a video interview with Pharma Commerce, Boyede Sobitan, global healthcare strategy lead, and Annika Matas, senior director of product management and business operations, supplies and sensors—both with Zebra Technologies—they describe how…

The Prescription Information Modernization Act of 2025 (PIMA) is being hailed as a significant development for the pharmaceutical industry because it represents rare bipartisan agreement on an issue that directly impacts both healthcare providers and patients. In a video interview with Pharma Commerce, Diogo Rau, executive vice president and chief…

Image Credit: Adobe Stock Images/Philip.com Last night, the Trump administration requested that the US Supreme Court hear out an appeal to overturn a previous ruling by a lower court declaring that a majority of his tariffs are null and void.1,2 In a 7-4 decision, the US Court of Appeals for…

The Prescription Information Modernization Act of 2025 (PIMA) is being hailed as a significant development for the pharmaceutical industry because it represents rare bipartisan agreement on an issue that directly impacts both healthcare providers and patients. In a video interview with Pharma Commerce, Diogo Rau, executive vice president and chief…

Image Credit: Adobe Stock Images/MichaelVi.com Amgen will be financially committing upwards of $600 million into a new, state-of-the-art, science and innovation center at its global HQ in Thousand Oaks, CA.1 Construction is anticipated to begin Q3 2025. The facility is intended to unite various stakeholders—including engineers, scientists, and researchers—across multiple areas as a way…

The Prescription Information Modernization Act of 2025 (PIMA) is being hailed as a significant development for the pharmaceutical industry because it represents rare bipartisan agreement on an issue that directly impacts both healthcare providers and patients. In a video interview with Pharma Commerce, Diogo Rau, executive vice president and chief…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re highlighting encouraging progress in flu vaccination rates, a new AI-driven partnership in RNA therapeutics, and concerns about how…

In a video interview with Pharma Commerce, Dave Malenfant, a healthcare supply chain expert, discusses the potential impact of a proposed 250% tariff on pharmaceutical imports, emphasizing that the effect depends heavily on where in the supply chain the tariff is applied. If imposed on active pharmaceutical ingredients (APIs), the…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new research on vaccine protection, Eli Lilly’s pause in UK shipments of Mounjaro, and the FDA’s response…

This video was created based on various Pharma Commerce articles: AbbVie Invests $195 Million to Expand Stateside API Manufacturing AstraZeneca Commits $50 Billion to US Manufacturing and R&D Efforts by 2030 Battelle and Aprecia Partner With HHS and DARPA to Advance Agile Drug Manufacturing Genentech Breaks Ground on $700M North…

Image Credit: Cold Chain Technologies Cold Chain Technologies (CCT), is solidifying its commitment to growing its Asia-Pacific (APAC) presence by continuing to seek out new investment and partnership opportunities across the region.1 These new initiatives aim to combine CCT’s global expertise with its local resources in order to strengthen support…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a high-profile leadership dispute at the CDC, the persistence of drug shortages, and the FDA’s approval of…

Pharmaceutical Commerce presents The Most Favored Nation Mandate webinar! Earlier this year, Donald Trump issued an executive order stating that pharma companies must treat the United States as a most-favored-nation (MFN). Essentially, the order states that drug prices in the US should at least match the lowest price across the…

Image Credit: Adobe Stock Images/KKStock.com With an increase in price forthcoming, Eli Lilly has decided to temporarily pause UK shipments of Mounjaro1—the company’s branded form of tirzepatide that is approved for the treatment of type 2 diabetes in adults—until Sept. 1. This signifies that pharmacies will not be able to…

Thani Jambulingam, PhD, professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business, outlines examples of obstacles faced by the pharma supply chain, supply chain vulnerabilities, and lessons learned in risk mitigation, while sharing advice on how companies can plan for future disruptions.…

In a video interview with Pharma Commerce, Dave Malenfant, a healthcare supply chain expert, discusses the potential impact of a proposed 250% tariff on pharmaceutical imports, emphasizing that the effect depends heavily on where in the supply chain the tariff is applied. If imposed on active pharmaceutical ingredients (APIs), the…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering updates in maternal health guidance, real-world diabetes data, and a new partnership aimed at lowering drug costs…

Credit: Tada Images | stock.adobe.com The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for…

Image Credit: Adobe Stock Images/Stas_Malyarevsky.com EVERSANA, a global services provider to the life sciences sector, and Waltz Health, a digital health company centered around prescription care, are uniting to create a healthcare platform that brings a new perspective to the pharma commercialization and patient access market. By partnering up, Waltz…

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering FDA safety concerns at a major Novo Nordisk facility, the growing trend of off-label GLP-1 prescribing, and…

Image Credit: Adobe Stock Images/TadaImages.com Novo Nordisk has some facility issues to address. As first reported by STAT News,1 the company’s Bloomington, IN plant that was acquired as part of last year’s Catalent acquisition2 has received an FDA Form 483. This type of citation3,4 is typically given following an inspection…

Image Credit: Adobe Stock Images/DreamerStudio.com DSCSA stands for the Drug Supply Chain Security Act, and is enforced by the FDA. It was originally signed into law aspart of the Drug Quality and Security Act (DQSA) in November of 2013 as a way to help bolster security and traceability of products…

Image Credit: Adobe Stock Images/MichaelVi.com Johnson & Johnson is all in on domestic manufacturing. The company announced plans to boost its North Carolina presence by constructing a 160,0000-plus-square-foot manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, NC.1 The $2 billion investment in the contract development and manufacturing organization…

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering updates on international trade, a US manufacturing investment, and new federal rules shaping electronic health records. The…

Image Credit: Adobe Stock Images/ImagingL.com Following an eight-day bench trial, a judge has issued a final judgement ruling that pharmacy benefits manager Caremark—a subsidiary of CVS Health—must pay $289.9 million in damages to Sarah Behnke, in a False Claims Act whistleblower case.1 Caremark plans to appeal the decision. In June, the…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

In a recent interview with Pharmaceutical Commerce, Ron Lanton, partner at Lanton Law, discussed the high-stakes implications of a new lawsuit filed by leading medical organizations to restore access to COVID-19 vaccines for children and pregnant people. Lanton explained how the case reflects deeper tensions between scientific standards, federal authority, and…

Image Credit: Adobe Stock Images/Aquir.com As noted by Pharm Exec,1 the White House and European Union today revealed a framework for a deal centered around “reciprocal, fair, and balanced trade” that is expected to get into effect Sept. 1 of this year. Although the agreement covers all imported goods coming…

In a recent interview with Pharmaceutical Commerce, Ron Lanton, partner at Lanton Law, discussed the high-stakes implications of a new lawsuit filed by leading medical organizations to restore access to COVID-19 vaccines for children and pregnant people. Lanton explained how the case reflects deeper tensions between scientific standards, federal authority,…

In a video interview with Pharma Commerce, Dave Malenfant, a healthcare supply chain expert, discusses the potential impact of a proposed 250% tariff on pharmaceutical imports, emphasizing that the effect depends heavily on where in the supply chain the tariff is applied. If imposed on active pharmaceutical ingredients (APIs), the…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering advances in agile drug manufacturing, a multi-billion-dollar RNA therapy collaboration, and how pharmacists are using telehealth to…

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at a major regulatory milestone for Novo Nordisk, a promising new antiviral combination for influenza, and the…

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new digital access to GLP-1 therapies, a clinical trial setback for Pfizer, and the pros and cons…

It’s been about six months since the trade wars pitting the US vs. various global nations and regions have commenced, and in my unbiased opinion, Pharmaceutical Commerce has done as exceptional of a job as any news outlet in providing developments as they’ve ensued. As of press time—which was a…

Mike Hennessy Jr, chairman and CEO, MJH Life Sciences Every stakeholder’s role in the pharmaceutical supply chain is just as important as the next, and that certainly holds true for that of the drug wholesaler. Essentially, these businesses serve as an intermediary between manufacturers and the downstream chain—after buying medications…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering three major developments—from new US policy on drug manufacturing to a high-profile pricing change for a leading…

Image Credit: Adobe Stock Images/Thanayut.com Goodpath, a virtual clinic for chronic health conditions, has reached a pharmacy integration deal with GiftHealth, Eli Lilly and Company’s LillyDirect pharmacy provider.1 LillyDirect is Lilly’s direct-to-consumer digital healthcare platform that was launched back in January 2024.2 It’s known for providing resources for disease management, featuring access to…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Welcome to the explainer. Today, we are talking about the wild and honestly, super complex world of drug pricing, and we’re going to tackle what some experts call the gross-to-net bubble. It’s a huge shift that’s happening right now, and you need to know about it. So let’s just jump…

View the Pharmaceutical Commerce August 2025 issue in an interactive format.

Future Focal Points for Distributors Deepen specialty and MSO integration. Continue expanding into management service organizations and specialty care networks to strengthen relationships with independent practitioners, secure high-margin specialty drug channels, and create clinical trial and patient outcome data synergies with manufacturers. Advance cell and gene therapy readiness. Invest in…

In a video interview with Pharma Commerce, Mark Lee, MarqVision’s founder and CEO, highlights the rapid growth and increasing sophistication of the counterfeit pharmaceutical market, driven in large part by bad actors leveraging artificial intelligence (AI). Counterfeiters are now using AI to replicate authentic pharmaceutical packaging with high accuracy, build…

Daniel J. Gandor, EVERSANA Key Takeaways True omnichannel in pharma is a unified, customer-first marketing model—not just digital or multichannel tactics—requiring all teams and channels to work in harmony. Success depends on four pillars: deep customer understanding, consistent insight capture, data-driven personalization, and orchestrated customer journeys. Overcoming internal silos, aligning…

In a video interview with Pharma Commerce, Dave Malenfant, a healthcare supply chain expert, discusses the potential impact of a proposed 250% tariff on pharmaceutical imports, emphasizing that the effect depends heavily on where in the supply chain the tariff is applied. If imposed on active pharmaceutical ingredients (APIs), the…

Key Takeaways High-profile counterfeit medicine cases—from the 2019 Kentucky SURGICEL incident to counterfeit HIV drugs and Ozempic—expose vulnerabilities in the US healthcare supply chain, especially via unauthorized “gray market” channels. Criminal networks exploit forged documentation, fake packaging, and corrupt distributors to infiltrate regulated supply chains with dangerous products. Despite strict…

Key Takeaways Patient access to treatment remains poor. For the second year in a row, patients with chronic conditions rated health plan access a “D,” with nearly half facing insurance-related barriers like high cost-sharing, formulary restrictions, and prior authorization. Barriers are worsening in 2025. Over a third of chronically ill…

Key Takeaways GSK discontinued Flovent HFA and replaced it with a generic to avoid new Medicaid rebate rules that would have required them to pay more in rebates than they made in sales. The move led to higher patient costs and reduced access, as many insurers didn’t cover the generic,…

Image Credit: Adobe Stock Images/Ibnu.com Novo Nordisk recently filed 14 new lawsuits intended to protect patients from unapproved compounded drugs that falsely claim to contain semaglutide. The defendants that are mentioned in the lawsuits claim that these compounded products have been both reviewed and approved by the FDA, or are…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we’re looking at how grocery-based pharmacies are transforming into vital community health hubs—right in the aisles where…

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we have three major stories—from strategic restructuring to clinical breakthroughs, and a high-stakes legal decision—each with big…

Image Credit: Adobe Stock Images/PostmodernStudio.com At a time when more than 50% of pharmaceuticals distributed in the United States are produced overseas, the FDA has introduced PreCheck, a new program intended to fortify the domestic pharma supply chain by boosting regulatory reliance and encouraging the development of US manufacturing facilities.1…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

In the highly regulated world of life sciences, compliance isn’t just a box to check; it is the foundation of product quality, patient safety, and business viability. GxP guidelines, encompassing all aspects from manufacturing and clinical trials to data management and personnel training, are designed to ensure that pharmaceutical and…

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure…

Image Credit: Adobe Stock Images/DavideBonaldo.com Last week, President Trump issued letters to 17 of the largest pharmaceutical companies, expressing dire urgency for making changes along the drug pricing front.1 These letters date back to an executive order (EO) he enacted in May that essentially proclaimed that pharma companies need to treat…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of US supply chain, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as Zenk notes, “all…

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of US supply chain, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as Zenk notes, “all…

In a video interview with Pharma Commerce, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, he describes how the One Big Beautiful Bill Act (OBBBA) is expected to significantly influence prescription drug spending by reshaping access and reimbursement within Medicaid, certain Medicare segments, and ACA exchange plans. The OBBBA introduces pressure…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of supply chain operations & distribution services, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as…

In a video interview with Pharma Commerce, Nate Chenenko, principal with Ducker Carlisle, sheds light on the critical issue of Scope 3 emissions and their growing relevance in the pharmaceutical industry, particularly across warehousing, packaging, and outbound transportation. Chenenko defines Scope 3 emissions as all indirect emissions that occur after…

What Clinical Ops Teams Must Know About Biomarkers in Trials In an interview with Applied Clinical Trials, Michael Miller, COO of Quanterix, emphasized that clinical operations teams must carefully consider the purpose, technical requirements, and regulatory implications of biomarkers in trials—especially as their use expands in neurology, oncology, and platform…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of supply chain operations & distribution services, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as…

Credit: Ascannio | stock.adobe.com. The FDA has issued a second complete response letter (CRL) to Regeneron’s odronextamab based on issues with a third-party manufacturing site, Catalent Indiana LLC, the company announced in its Q2 earnings report.1 Regeneron’s Biologics License Application (BLA) is seeking the approval of odronextamab for the treatment…

As reported by Pharma Commerce sister publication, Pharmaceutical Executive,1 President Trump recently issued letters to 17 of the largest pharmaceutical companies, expressing urgency for making changes along the drug pricing front. These letters stem from an executive order (EO) he enacted in May1 that essentially proclaimed that pharma companies need…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Image Credit: Adobe Stock Images/AMuhSakaria.com As large pharmacy retailers scale back operations, community pharmacies—particularly those embedded within grocery stores—are stepping into expanded roles as accessible healthcare touchpoints. This shift reflects a broader trend toward integrating healthcare services into everyday consumer environments, enhancing patient engagement and access to care. “Pharmacies today…

In a video interview with Pharma Commerce, Nate Chenenko, principal with Ducker Carlisle, sheds light on the critical issue of Scope 3 emissions and their growing relevance in the pharmaceutical industry, particularly across warehousing, packaging, and outbound transportation. Chenenko defines Scope 3 emissions as all indirect emissions that occur after…

Where Has AI Already Been Successfully Implemented? In an interview with Pharmaceutical Executive, Gen Li, president and founder of Phesi, discussed how AI has already been successfully implemented in partnership with several top pharmaceutical companies to improve clinical trial design, patient recruitment, and site performance—particularly through the use of digital…

In a video interview with Pharma Commerce, Nate Chenenko, principal with Ducker Carlisle, sheds light on the critical issue of Scope 3 emissions and their growing relevance in the pharmaceutical industry, particularly across warehousing, packaging, and outbound transportation. Chenenko defines Scope 3 emissions as all indirect emissions that occur after…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of supply chain operations & distribution services, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as…

In a video interview with Pharma Commerce, Heather Zenk, Cencora’s president of supply chain operations & distribution services, describes how today’s distribution networks must seamlessly connect manufacturers to care sites that range from large academic centers to rural pharmacies and physician offices. This “last mile” delivery is essential because, as…

In a video interview with Pharma Commerce, Hyung Heon Kim, CEO of MetaVia, describes how the current US payer ecosystem, including commercial insurers and Medicaid, exhibits a divided approach when it comes to supporting access to obesity medications. Coverage largely depends on whether obesity is accompanied by additional health complications.…

Rethinking Oncology Trials with a Statistical Methodology That Puts Patients First In an interview with Applied Clinical Trials, experts discussed how the Net Treatment Benefit statistical methodology—rooted in generalized pairwise comparisons—is helping reshape oncology trial design by prioritizing patient-centered outcomes such as quality of life and toxicity alongside survival, enabling…

In a video interview with Pharma Commerce, Nate Chenenko, principal with Ducker Carlisle, sheds light on the critical issue of Scope 3 emissions and their growing relevance in the pharmaceutical industry, particularly across warehousing, packaging, and outbound transportation. Chenenko defines Scope 3 emissions as all indirect emissions that occur after…

In a video interview with Pharma Commerce, Hyung Heon Kim, CEO of MetaVia, describes how the current US payer ecosystem, including commercial insurers and Medicaid, exhibits a divided approach when it comes to supporting access to obesity medications. Coverage largely depends on whether obesity is accompanied by additional health complications.…

Balancing DEI Reporting with Legal Risk In an interview with Applied Clinical Trials, Kate Gallin Heffernan, a life sciences attorney at Epstein Becker Green, discussed how clinical research teams can balance accurate DEI-related reporting with minimizing legal risk, emphasizing the need for careful language and documentation to avoid potential False…

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes how a proposed 200% tariff on pharmaceutical imports could have significant short- and long-term impacts on US drug manufacturing and distribution, with immediate concerns focused on the stability of the generic drug market. According to…

Sixty percent of life sciences and healthcare leaders are anticipating that the current or forthcoming tariffs and pricing policies will have “some impact” on their businesses. Image Credit: Adobe Stock Images/Thanawat_Suesoypan.com According to the Deloitte Center for Health Solutions’ “2025 Tariffs, Pricing, and Taxes Survey,”1 60% of life sciences and…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Image Credit: Adobe Stock Images/Sardar Key Takeaways Expanded Educational Access: Cold Chain Technologies (CCT) partners with E&I Cooperative Services to provide over 6,000 educational institutions expedited access to advanced cold chain packaging solutions. Streamlined Procurement Process: The partnership enables members to bypass lengthy RFP procedures, accelerating acquisition of temperature-controlled packaging…

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes how a proposed 200% tariff on pharmaceutical imports could have significant short- and long-term impacts on US drug manufacturing and distribution, with immediate concerns focused on the stability of the generic drug market. According to…

Patient safety and medication adherence are some of the major concerns in the pharmaceutical industry. With an increase in medication errors, counterfeit medicines, and supply chain mismanagement, the industry has seen a rising demand for transparency, security, engagement, and digitization.1 Smart packaging has emerged as a key solution to address…

In a video interview with Pharma Commerce, Hyung Heon Kim, CEO of MetaVia, describes how the current US payer ecosystem, including commercial insurers and Medicaid, exhibits a divided approach when it comes to supporting access to obesity medications. Coverage largely depends on whether obesity is accompanied by additional health complications.…

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes how a proposed 200% tariff on pharmaceutical imports could have significant short- and long-term impacts on US drug manufacturing and distribution, with immediate concerns focused on the stability of the generic drug market. According to…

In a video interview with Pharma Commerce, Hyung Heon Kim, CEO of MetaVia, describes how the current US payer ecosystem, including commercial insurers and Medicaid, exhibits a divided approach when it comes to supporting access to obesity medications. Coverage largely depends on whether obesity is accompanied by additional health complications.…

In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes how a proposed 200% tariff on pharmaceutical imports could have significant short- and long-term impacts on US drug manufacturing and distribution, with immediate concerns focused on the stability of the generic drug market. According to…

In a video interview with Pharma Commerce, Hyung Heon Kim, CEO of MetaVia, describes how the current US payer ecosystem, including commercial insurers and Medicaid, exhibits a divided approach when it comes to supporting access to obesity medications. Coverage largely depends on whether obesity is accompanied by additional health complications.…

In a video interview with Pharma Commerce, Sean O’Hearen, founder and principal consultant at 1st Line Partners, discusses the critical issue of substandard and falsified (SF) medicines and the lack of awareness among healthcare professionals (HCPs). Despite SF drugs posing a growing global health risk, only 2% of HCPs are…

In a video interview with Pharma Commerce, Murray Aitken, executive director of the IQVIA Institute for Human Data Science, explains the extensive process behind developing the “Global Use of Medicines Outlook Through 2029” report. The creation of this comprehensive resource spans several months and integrates proprietary IQVIA datasets, including the…

President Trump noted that the pharma sector should prepare for levies by the beginning of next month, which could coincide with the planned reciprocal tariffs rates that were previously set. Image Credit: Adobe Stock Images/FreshIdea.com Earlier this week, per Bloomberg, President Trump told reporters that the pharmaceutical sector should prepare…

In a video interview with Pharma Commerce, Murray Aitken, executive director of the IQVIA Institute for Human Data Science, explains the extensive process behind developing the “Global Use of Medicines Outlook Through 2029” report. The creation of this comprehensive resource spans several months and integrates proprietary IQVIA datasets, including the…

How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies In an interview with Applied Clinical Trials, Shipra Patel, global therapeutic area section head for endocrinology and global head of pediatrics at Parexel, explained how the company supports cross-functional GLP-1 trials by leveraging therapeutic alignment, real-world evidence, and collaborative infrastructure…

Resilience, which is the concept of defying adversity and recovering from hardship, is connected to one’s health and well-being. Image Credit: Adobe Stock Images/Jaman_Visual.com Resilience, which is the concept of defying adversity and recovering from hardship, is connected to one’s health and well-being.1 However, on the other hand, via behavioral,…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

In a video interview with Pharma Commerce, Sean O’Hearen, founder and principal consultant at 1st Line Partners, discusses the critical issue of substandard and falsified (SF) medicines and the lack of awareness among healthcare professionals (HCPs). Despite SF drugs posing a growing global health risk, only 2% of HCPs are…

In a video interview with Pharma Commerce, Sean O’Hearen, founder and principal consultant at 1st Line Partners, discusses the critical issue of substandard and falsified (SF) medicines and the lack of awareness among healthcare professionals (HCPs). Despite SF drugs posing a growing global health risk, only 2% of HCPs are…

Chandler’s pharmaceutical experience spans years in the pharma services space, powered by strategic leadership roles. Image Credit: Knipper Health Following Frazier Healthcare Partners’ investment in Knipper Health, Willis Chandler has officially been appointed as Knipper’s president and CEO.1 How exactly does Knipper aim to get patients started on treatment at…

LEO Pharma will pay Boehringer Ingelheim $105.2 million (€90 million) upfront, with the opportunity for additional payment, if specific milestones are met. Image Credit: Adobe Stock Images/JHVEPhoto.com Boehringer Ingelheim and LEO Pharma have reached an exclusive global license and transfer agreement for the commercialization and further development of Spevigo, a…

Gilead plans to supply enough doses to assist up to two million individuals over three years in nations supported by the Global Fund. Image Credit: Adobe Stock Images/TobiasArhelger.com Gilead Sciences is collaborating with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to provide lenacapavir for the prevention…

Few times in the evolution of a pharmaceutical company are as exciting as during the flurry of launch readiness activities focused on bringing a new drug to market. From the new drug application (NDA) submission to the Prescription Drug User Fee Act (PDUFA) date, the brand team is fully engaged—selecting…

Removing Financial Barriers to Boost Trial Diversity In an interview with Applied Clinical Trials, Heather Horville, solutions consultant, Greenphire, emphasized the importance of removing financial and logistical barriers—such as through reimbursements, stipends, and prepaid travel—to improve clinical trial diversity and retention, stressing the need for early planning, site-level coordination, and…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Despite these medications being both available and affordable, racial, ethnic, and socioeconomic disparities came to light when it came to accessing COVID-19 treatment. Image Credit: Adobe Stock Images/Steheap.com As history has shown, being able to act fast when it comes to outpatient treatment for a COVID-19 infection provide a high…

In a video interview with Pharma Commerce, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, addresses the potential impacts of a federal cap on Medicaid provider taxes and how such a policy could affect hospital systems. particularly in states…

PC: In the absence of public participation at the federal level, how can industry leaders collaborate with advocacy groups to sustain meaningful engagement with regulators? Leuchter: Experienced regulators are very attuned to how patients and caregivers live day to day with a given disease. That understanding is a key part…

In a video interview with Pharma Commerce, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, addresses the potential impacts of a federal cap on Medicaid provider taxes and how such a policy could affect hospital systems. particularly in states…

July 9, 2025 Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit. Not every…

President Trump noted that import taxes on pharmaceuticals of up to 200% could come forthcoming. Image Credit: Adobe Stock Images/MohammadXte.com The pharmaceutical industry has been anxiously standing by, waiting on the possibility that tariffs on imports entering the United States could take effect, just not at this potential level. There…

PC: How might this change affect payer negotiations and reimbursement decisions, particularly for innovative or high-cost therapies? Leuchter: When it comes to rare diseases, patients often suffer from a wide range of symptoms—some of which receive more attention from drug developers than others. That’s often because targeting specific symptoms can…

All of the levies come with a stipulation—if these nations increase their tariffs, the United States will raise them on its end as well. Image Credit: Adobe Stock Images/Zenday.com Yesterday, per AP and CBS News,1,2 US President Donald Trump enacted a multitude of tariffs expected to go into effect on…

A qualitative study explored how representatives from MA plans, kidney care management companies, and dialysis organizations view the expansion and marketing of MA products for individuals with ESKD. Image Credit: Adobe Stock Images/CrystalLight.com By this year, enrollment in Medicare Advantage (MA) plans, which feature private managed care insurers to receive…

The trust gap between real-world evidence (RWE)/data and randomized controlled trials is growing. This episode examines when each evidence type is appropriate, how to reduce perceived bias in RWE, and how payer context varies by geography and structure. Insights from academic and payer partnerships show how joint research can establish…

2025 DIA Annual Meeting: Building Patient Centricity into Clinical Trial Software from Day One In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer, uMotif, discussed how the company integrates patient and site feedback from the earliest stages of software development to create intuitive, regulatory-ready digital health tools…

PC: What risks do you foresee for companies developing first-in-class therapies if patient perspectives are no longer formally incorporated into regulatory discussions? Leuchter: Eliminating patient perspectives from regulatory discussions would remove a key source of value—especially in the context of rare or recently characterized diseases. In many of these cases,…

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted significant progress in key operational areas, noting that companies are now better prepared for commercial launches than in the past. Early challenges…

Preparing for Federal Regulations: Q&A with John Stanford In an interview with Pharmaceutical Executive, John Stanford, executive director at Incubate, emphasized the importance of sustained investment in early-stage biotech to drive long-term innovation and ensure a robust drug development pipeline. Funding Cuts Threaten Diversity in Clinical Research In an interview…

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from CGT’s highly specialized operational strategies, particularly in terms of supply chain resilience and adaptability.

Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment In an interview with Pharmaceutical Executive, Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shared how insights from the company’s Oncology Care Index are shaping efforts to reduce fragmentation in cancer care by expanding community-based…

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has significantly disrupted access for patients who relied on these lower-cost alternatives, prompting Olympia Pharmaceuticals to shift its focus to legal and in-demand…

This investment exemplifies Hikma’s interest in raising the volume of meds it creates and produces across its various R&D and manufacturing sites in Columbus and Cleveland, OH and in Cherry Hill and Dayton, NJ. Image Credit: Adobe Stock Images/Deep.com Hikma Pharmaceuticals USA today will be financially committing $1 billion by the year 2030 to further grow its US manufacturing and R&D…

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted significant progress in key operational areas, noting that companies are now better prepared for commercial launches than in the past. Early challenges…

Historically, new drugs were approved for a single therapeutic use. However, industry trends have shifted, with pharmaceutical companies increasingly identifying and developing additional indications for existing medicines. This approach is supported by regulatory agencies such as the FDA and EMA, which recognize the value of leveraging established safety profiles for…

PC: What role has public participation historically played in shaping healthcare policy, and why is it important for pharma and biotech companies? Leuchter: Public participation has played a critical role, for many of the reasons I mentioned earlier. But I’d like to expand on one area I haven’t touched on…

Medicaid is especially critical for children with rare diseases, due to their need for intensive specialty care and higher risk for financial distress. Image Credit: Adobe Stock Images/Ivlianna.com In the United States, Medicaid is considered the largest payer of healthcare, serving nearly a quarter of the total population; this includes…

Novo Nordisk is growing coverage of its Wegovy injection 2.4 mg in the form of a new deal with WeightWatchers that takes effect July 1. Image Credit: Adobe Stock Images/Syahrir.com Novo Nordisk is growing coverage of its Wegovy (semaglutide) injection 2.4 mg in the form of a new deal with WeightWatchers…

Real-world evidence (RWE) is no longer optional—it’s expected. This episode dives into how payers assess RWE alongside clinical trial data, especially in competitive therapeutic areas. The panel stresses the importance of linking RWE to financial outcomes and making data relevant to specific patient populations. It’s not just about data quality;…

2025 DIA Annual Meeting: The Importance of Early Patient Feedback in Digital Endpoint Development In an interview with Applied Clinical Trials at the 2025 DIA Annual Meeting, Brian Ongioni, chief product officer, uMotif, emphasized the importance of incorporating early patient and site feedback into the digital health product lifecycle to…

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted significant progress in key operational areas, noting that companies are now better prepared for commercial launches than in the past. Early challenges…

How CRO Partnerships Are Evolving to Meet Changing Industry Demands In an interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer, Novotech, emphasized the need for CRO partnerships to become more collaborative, cost-efficient, and insight-driven in response to evolving regulatory and funding challenges, highlighting Novotech’s award-winning collaboration with…

2025 DIA Annual Meeting: How AI and Machine Learning Can Improve Patient Reported Outcomes in Clinical Trials In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer at uMotif, explained how the company integrates patient and site feedback early in the development process to improve the usability and…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Pharmaceutical Commerce: FDA staff cuts have created a critical gap in adverse drug event (ADE) monitoring. With ADEs being the third leading cause of death in the United States,1 what role do you see AI playing in preventing these events, especially when up to 56% are considered preventable through faster…

Investigators aimed to examine the quality and efficiency under the FFS MA and at-risk MA models as a way to measure both the quality and resources that are being utilized. Image Credit: Adobe Stock Images/SatoriStudio.com More than 50% of Medicare beneficiaries elect to join Medicare Advantage (MA), which has out-of-pocket…

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted significant progress in key operational areas, noting that companies are now better prepared for commercial launches than in the past. Early challenges…

The purpose of the partnership is to help further develop the Treg and TIL cell therapies that are intended to fight autoimmune and solid tumor diseases. Image Credit: Adobe Stock Images/Zuraara.com Xcell Biosciences (Xcellbio), an instrumentation company that focuses on cell and gene therapy (CGT) applications, is teaming up Thermo…

As international price referencing tightens and payer expectations rise, companies face a shrinking margin for error. The panel explores how clinical trial design and early payer engagement are key to meeting both regulatory and reimbursement demands across global markets. With real-world evidence (RWE) from markets like Korea and Japan in…

Stop Losing Patients at the Gate: The 24-Hour Window That Makes or Breaks Your Entire Hub Program

Image Credit: Adobe Stock Images/TadaImages.com As a result of the Patient Protection and Affordable Care Act (ACA), 24.2 million people enrolled in the health insurance marketplaces this year, a record number.1 However, sustaining that coverage can potentially be a major challenge, given the administrative obstacles that they can face. Why…

Image Credit: Adobe Stock Images/StockMediaLabs.com Evaluate, who provides market insights for the pharma industry, has unveiled its “2025 World Preview Report,” which offers insights for the global pharmaceutical market through the year 2030.1,2 The breakdown is headlined by the prediction that worldwide prescription pharmaceutical sales will grow at a compound…

This Peer Exchange® starts off with an introduction of the panel: Edward Ahn, CEO of MEDIPOST, Inc.; Rob Philo, Founder and CEO of Core Market Access Advisors; and Shana Gunderson Hua, PharmD, Vice President of Value & Access at Petauri Advisors. Moderated by Ed Schoonveld, Value and Access Advisor at…

Pharmaceutical Commerce: June 2025 Interactive Digital Edition DSCSA Compliance: The Time is Now Conference Connect: Determining the Future of Specialty Pharmacy Bolstering Health Technology Assessment With the Help of AI Building Intelligent Pharma Supply Chain Management with Real-World Data Policy Whiplash? 24 Hours in the Hub Still Matters More Financial…

TekniPlex Healthcare, a supplier of barrier films, unit-dose containers, and more, has opened its new 200,000-square-foot facility in Madison, WI, which was made official with a ribbon-cutting ceremony last week. The new site—representing its second Madison plant—acts as the flagship location for the company’s barrier protection systems business, and will strive…

Strategic Planning in the Rebate Economy: What Pharma Must Do Now A recent Pharmaceutical Executive article outlines how, despite decades of evolving policy from OBRA ’90 to the Inflation Reduction Act, the US pharmaceutical system remains deeply reliant on manufacturer rebates—prompting drugmakers to shift from workaround tactics to strategic execution…

Building Strong CRO-Sponsor Partnerships to Improve Clinical Trial Success In an interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer at Novotech, emphasized the value of trust-based CRO-sponsor relationships and celebrated the company’s Citeline CRO Partnership of the Year Award for its collaboration with Tune Therapeutics as a…

AI-GO blister inspection. Image Credit: Antares Vision Group Antares Vision Group, a provider of track-and-trace systems for several fields including the life sciences, and Oròbix, an artificial intelligence (AI) service company that’s part of Antares, have launched AI-GO, an AI-powered visual inspection platform that is expected to boost standards that…

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply…

Image Credit: Adobe Stock Images/DigitalMagicVisions.com One of several public health issues of utmost importance are mental health disorders, which are quite commonplace. In the United States, millions of adults suffer from psychological distress, which can significantly impair their ability to carry out major life activities.1 Given its impact, patients, clinicians,…

In a video interview with Pharma Commerce, LeAnn Boyd, PharmD, Liviniti’s founder and CEO, discusses the deeper, systemic issues behind rising healthcare and drug costs that are not fully addressed by the MFN (Most-Favored Nation) executive order. She acknowledges that the healthcare landscape has seen incredible advancements in therapies that…

Image Credit: Adobe Stock Images/Rawpixel.com Data show that nearly two-thirds of Medicare beneficiaries feel that their coverage completely meets their expectations. Despite this, a recent survey also showed that 15% of Medicare beneficiaries changed their coverage in the past two years, while another 6% had the intention of doing so,…

Key Takeaways DSCSA enforcement deadlines are phasing in through 2025, with wholesalers and repackagers already required to comply as of May 27, and wholesale distributors facing an August 27 deadline—provided they show active progress on data connections. Despite past delays and exemptions, industry stakeholders report significant progress, with data connectivity…

Key Takeaways AI enhances traditional HTA by improving accuracy and efficiency. Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. AI supports personalized medicine and real-world evidence integration.…

Key Takeaways Real-world data enhances medication safety and supply chain efficiency. By collecting and applying data from manufacturing through administration, stakeholders can optimize inventory, track usage trends, and improve predictive analytics to ensure medication availability and safety. Advanced tracking technologies like RFID improve visibility and reduce risks. Continuous, real-time monitoring…

Key Takeaways Speed is Critical. The first 24 hours after a prescription are crucial—nearly half of patients are lost immediately without efficient onboarding. Rapid, streamlined hub services are essential to keep patients engaged and on therapy. Digital and Multichannel Enrollment Is Key. Combining traditional methods (fax, phone) with digital tools…

Image Credit: Adobe Stock Images/JHVEPhoto.com Key Takeaways UCB is investing $5 billion in a new US biologics manufacturing facility, aiming to boost its production capabilities, create 800 jobs, and strengthen its global supply chain. The company’s US expansion reflects a broader industry trend, with major biopharma firms like Regeneron, Roche,…

In a video interview with Pharma Commerce, Kirsten Newquist, Identiv’s CEO, defines “smart pharma packaging” as the integration of technology into pharmaceutical packaging to enhance product identification, tracking, and patient engagement. She explains that packaging primarily involves embedding technologies such as RFID radio-frequency identification (RFID) or Bluetooth low energy (BLE)…

Navigating the Intersection of Accessibility and Measurement Integrity in eCOA An article in Applied Clinical Trials explores how clinical research’s shift toward patient-centered outcomes is prompting the eCOA field to reconcile long-standing tensions between accessibility and measurement integrity, calling for the integration of modern accessibility standards to ensure digital tools…

In a video interview with Pharma Commerce, Kirsten Newquist, Identiv’s CEO, defines “smart pharma packaging” as the integration of technology into pharmaceutical packaging to enhance product identification, tracking, and patient engagement. She explains that packaging primarily involves embedding technologies such as RFID radio-frequency identification (RFID) or Bluetooth low energy (BLE)…

Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry’s ability to raise drug prices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone. PBMs enabled the bubble through rebate structures. PBMs often…

Sticker shock at the pharmacy counter has become an all-too-familiar experience for both patients and providers. The rising cost of prescription medications in the United States creates a growing obstacle for millions of people. In 2022, more than 4,200 drug products experienced price increases (many of which were higher than…

Image Credit: Adobe Stock Images/Tippapatt.com Key Takeaways DHL has acquired Cryoport’s specialty courier business, CRYOPDP, for approximately $200 million, strengthening its position in temperature-controlled logistics for the life sciences sector. A strategic partnership between DHL and Cryoport has been formed to enhance global supply chain capabilities, particularly in the APAC…

June 12, 2025 Amy Niles, chief mission officer, PAN Foundation, provides a deep dive into patient awareness of financial assistance programs, while offering insights into health literacy related to medical plans.

Image Credit: Adobe Stock Images/BeaunittaVanWyk.com Key Takeaways Alzheimer’s disease affects nearly 6.9 million older U.S. adults, making it the most common form of dementia and a leading cause of long-term care needs and disability. The economic burden of ADRD is substantial and rising, with costs projected to increase from nearly…

In a video interview with Pharma Commerce, Maggie McCullough, PolicyMap’s CEO, highlights how geospatial mapping can play a critical role in identifying and addressing pharmacy deserts—areas where access to pharmacies is limited or nonexistent. With an estimated 17.7% of the US population affected, the issue is increasingly urgent, particularly as…

Image Credit: Adobe Stock Images/Nattakorn.com Key Takeaways Language barriers reduce access to video-based virtual care: Adult patients facing language barriers are significantly less likely to use video visits compared to telephone visits, especially in specialist care settings. Overall virtual care use isn’t drastically different: There is no significant difference in…

In a video interview with Pharma Commerce, Maggie McCullough, PolicyMap’s CEO, highlights how geospatial mapping can play a critical role in identifying and addressing pharmacy deserts—areas where access to pharmacies is limited or nonexistent. With an estimated 17.7% of the US population affected, the issue is increasingly urgent, particularly as…

Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. Sanofi and AstraZeneca have tripled production capacity to meet growing demand. Beyfortus cut RSV hospitalizations by up to 83.2% and outperformed maternal vaccines in public…

PC: Although ways to decrease healthcare costs are certainly encouraged by pharma supply chain stakeholders, what potential long-term repercussions (if any) could President Trump’s MFN executive order have on the industry? Lanton: The executive order mandates that pharmaceutical companies match or beat the lowest price paid by certain countries—such as…

Preparing for the Pharma C-Suite In a Pharmaceutical Executive feature, Aileen Fernandes, Chief Business Officer at Arcellx, reflects on how her early roles at Morgan Stanley and Deloitte Consulting, combined with strategic career decisions and authentic leadership development, prepared her for biotechnology C-suite success and offers MBA students key advice…

Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them In a Pharmaceutical Executive feature, Gen Li, founder, CEO, Phesi, outlines five key challenges hindering investigator site selection in clinical trials—including unreliable performance predictions and lack of real-world data—and explains how clinical data science and…

Forging a Brighter Future for Rare Disease Outcomes with Specialty Pharmacy Utilization A Pharmaceutical Executive article explores how specialty pharmacy programs can significantly improve outcomes for patients with rare diseases—like cystic fibrosis—by providing faster access to treatment, better medication adherence, and personalized support that addresses the complex challenges of managing…

GLP-1 Drugs may be Linked to Elevated Risk of Serious Eye Disease, Study Finds A new observational study finds that people with diabetes taking GLP-1 drugs have a low but doubled risk of developing neovascular age-related macular degeneration, an eye disease that can cause blindness, highlighting the need for increased…